The emerging class of GLP-1 receptor agonist and GIP co-agonist medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, offer significant advances in metabolic control. https://hplcpeptidetesting067408.bloginwi.com/77637180/tirzepatide-one-comparative-examination